Effects of obesity and 10 weeks metformin treatment on liver steatosis

Hakkak,Reza; Rose,Shannon; Spray,Beverly; Kozaczek,Melisa; Korourian,Soheila

doi:10.3892/br.2021.1425

Effects of obesity and 10 weeks metformin treatment on liver steatosis

Authors:
- Reza Hakkak
- Shannon Rose
- Beverly Spray
- Melisa Kozaczek
- Soheila Korourian
View Affiliations

Affiliations: Department of Dietetics and Nutrition, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA, Arkansas Children's Research Institute, Little Rock, AR 72202, USA, Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Published online on: March 30, 2021 https://doi.org/10.3892/br.2021.1425
Article Number: 49
Copyright: © Hakkak et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑alcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in adolescents and adults, and the risk of developing NAFLD increases with obesity. In the present study, it was shown that obesity increased fatty liver (steatosis) using an obese Zucker rat model. Metformin is an oral anti‑hyperglycemic agent approved by the FDA for treatment of type 2 diabetes in adults and children >10 years of age. There is insufficient evidence regarding the effects of metformin on pediatric liver steatosis. Thus, in the present study, the effects of 10 weeks metformin treatment on liver steatosis and related serum markers for liver damage was assessed. Lean and obese (n=16 per group) 5‑week old female Zucker rats were provided an AIN‑93 G diet for 8 weeks to induce NAFLD, and then rats were randomly assigned to 4 groups (8 rats/group): i) lean without metformin (LC), ii) lean + metformin (LM), iii) obese without metformin (OC), and iv) obese + metformin (OM). Rats were provided ad libitum access to the diet containing metformin (1 g metformin per kg of food). Rats were weighed twice weekly and were sacrificed 10 weeks later. Serum was collected to measure the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), leptin and adiponectin. Livers were collected for histological analysis. The results showed that obese rats gained significantly more weight than lean rats in both the control and metformin treatment groups (P<0.001). OM treated rats exhibited a lower degree of liver steatosis compared with the OC rats (P<0.04). There were no significant differences in serum ALT levels between the groups. However, obesity significantly increased serum AST levels in both the control and metformin treatment groups (P=0.01). The ratio of leptin to adiponectin was increased in obese compared with the lean rats in both the control and metformin treatment groups (P<0.0001). There was no effect of metformin on serum biomarkers. In summary, short‑term metformin treatment decreased liver steatosis but did not affect the serum markers of liver steatosis.

View Figures

View References

1	Centers for Disease Control and Prevention: Adult Obesity Facts. CDC, 2020.
2	World Health Oraganization: Overweight and obesity. WHO, 2020.
3	Ogden CL, Carroll MD, Curtin LR, Lamb MM and Flegal KM: Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA. 303:242–249. 2010.PubMed/NCBI View Article : Google Scholar
4	Ogden CL, Carroll MD, Lawman HG, Fryar CD, Kruszon-Moran D, Kit BK and Flegal KM: Trends in obesity prevalence among children and adolescents in the United States, 1988-1994 through 2013-2014. JAMA. 315:2292–2299. 2016.PubMed/NCBI View Article : Google Scholar
5	Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL and Clark JM: Prevalence of nonalcoholic fatty liver disease in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 178:38–45. 2013.PubMed/NCBI View Article : Google Scholar
6	Angulo P: GI epidemiology: Nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 25:883–889. 2007.PubMed/NCBI View Article : Google Scholar
7	Welsh JA, Karpen S and Vos MB: Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr. 162:496–500.e1. 2013.PubMed/NCBI View Article : Google Scholar
8	Hakkak R, Al-Dwairi A, Fuchs GJ, Korourian S and Simmen FA: Dietary soy protein induces hepatic lipogenic enzyme gene expression while suppressing hepatosteatosis in obese female Zucker rats bearing DMBA-initiated mammary tumors. Genes Nutr. 7:549–558. 2012.PubMed/NCBI View Article : Google Scholar
9	Hakkak R, Zeng H, Dhakal IB and Korourian S: Short- and long-term soy diet versus casein protects liver steatosis independent of the arginine content. J Med Food. 18:1274–1280. 2015.PubMed/NCBI View Article : Google Scholar
10	Thomas I and Gregg B: Metformin; a review of its history and future: From lilac to longevity. Pediatr Diabetes. 18:10–16. 2017.PubMed/NCBI View Article : Google Scholar
11	Khokhar A, Umpaichitra V, Chin VL and Perez-Colon S: Metformin use in children and adolescents with prediabetes. Pediatr Clin North Am. 64:1341–1353. 2017.PubMed/NCBI View Article : Google Scholar
12	Luong DQ, Oster R and Ashraf AP: Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome. J Pediatr Endocrinol Metab. 28:649–655. 2015.PubMed/NCBI View Article : Google Scholar
13	Madiraju AK, Qiu Y, Perry RJ, Rahimi Y, Zhang XM, Zhang D, Camporez JG, Cline GW, Butrico GM, Kemp BE, et al: Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med. 24:1384–1394. 2018.PubMed/NCBI View Article : Google Scholar
14	Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G and Diehl AM: Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 6:998–1003. 2000.PubMed/NCBI View Article : Google Scholar
15	Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M and Melchionda N: Metformin in non-alcoholic steatohepatitis. Lancet. 358:893–894. 2001.PubMed/NCBI View Article : Google Scholar
16	Xu H, Zhou Y, Liu Y, Ping J, Shou Q, Chen F and Ruo R: Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis. J Endocrinol. 229:133–144. 2016.PubMed/NCBI View Article : Google Scholar
17	Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S and Yki-Järvinen H: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 53:2169–2176. 2004.PubMed/NCBI View Article : Google Scholar
18	Nair S, Diehl AM, Wiseman M, Farr GH Jr and Perrillo RP: Metformin in the treatment of non-alcoholic steatohepatitis: A pilot open label trial. Aliment Pharmacol Ther. 20:23–28. 2004.PubMed/NCBI View Article : Google Scholar
19	Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, et al: Nonalcoholic Steatohepatitis Clinical Research Network: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA. 305:1659–1668. 2011.PubMed/NCBI View Article : Google Scholar
20	Labruna G, Pasanisi F, Nardelli C, Caso R, Vitale DF, Contaldo F and Sacchetti L: High leptin/adiponectin ratio and serum triglycerides are associated with an ‘at-risk’ phenotype in young severely obese patients. Obesity (Silver Spring). 19:1492–1496. 2011.PubMed/NCBI View Article : Google Scholar
21	Korourian S, Hakkak R, Ronis MJJ, Shelnutt SR, Waldron J, Ingelman-Sundberg M and Badger TM: Diet and risk of ethanol-induced hepatotoxicity: Carbohydrate-fat relationships in rats. Toxicol Sci. 47:110–117. 1999.PubMed/NCBI View Article : Google Scholar
22	Zucker LM: Fat mobilization in vitro and in vivo in the genetically obese Zucker rat ‘fatty’. J Lipid Res. 13:234–243. 1972.PubMed/NCBI
23	Zucker LM and Zucker TF: Fatty, a new mutation in the rat. J Hered. 52:275–278. 1961.
24	Hakkak R, Gauss CH, Bell A and Korourian S: Short-term soy protein isolate feeding prevents liver steatosis and reduces serum ALT and AST levels in obese female zucker rats. Biomedicines. 6(6)2018.PubMed/NCBI View Article : Google Scholar
25	Zheng J, Woo SL, Hu X, Botchlett R, Chen L, Huo Y and Wu C: Metformin and metabolic diseases: A focus on hepatic aspects. Front Med. 9:173–186. 2015.PubMed/NCBI View Article : Google Scholar
26	Lu CH, Hung YJ and Hsieh PS: Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. Eur J Pharmacol. 789:60–67. 2016.PubMed/NCBI View Article : Google Scholar
27	Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, Ward GM and Cowell CT: Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: Improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 91:2074–2080. 2006.PubMed/NCBI View Article : Google Scholar
28	Love-Osborne K, Sheeder J and Zeitler P: Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr. 152:817–822. 2008.PubMed/NCBI View Article : Google Scholar
29	Burgert TS, Duran EJ, Goldberg-Gell R, Dziura J, Yeckel CW, Katz S, Tamborlane WV and Caprio S: Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 9:567–576. 2008.PubMed/NCBI View Article : Google Scholar
30	Wilson DM, Abrams SH, Aye T, Lee PD, Lenders C, Lustig RH, Osganian SV and Feldman HA: Glaser Pediatric Research Network Obesity Study Group. Metformin extended release treatment of adolescent obesity: A 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med. 164:116–123. 2010.PubMed/NCBI View Article : Google Scholar
31	Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P and Holshouser S: Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 50:1457–1461. 2001.PubMed/NCBI View Article : Google Scholar
32	Atabek ME and Pirgon O: Use of metformin in obese adolescents with hyperinsulinemia: A 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 21:339–348. 2008.PubMed/NCBI View Article : Google Scholar
33	El-Lakkany NM, Seif El-Din SH, Sabra AA, Hammam OA and Ebeid FA: Co-administration of metformin and N-acetylcysteine with dietary control improves the biochemical and histological manifestations in rats with non-alcoholic fatty liver. Res Pharm Sci. 11:374–382. 2016.PubMed/NCBI View Article : Google Scholar
34	Ghadge A, Harsulkar A, Karandikar M, Pandit V and Kuvalekar A: Comparative anti-inflammatory and lipid-normalizing effects of metformin and omega-3 fatty acids through modulation of transcription factors in diabetic rats. Genes Nutr. 11(10)2016.PubMed/NCBI View Article : Google Scholar
35	Sui Y, Kong X, Fan R, Ye Y, Mai H, Zhuo S, Lu W, Ruan P, Fang S and Yang T: Long-term treatment with metformin in the prevention of fatty liver in Zucker diabetic fatty rats. Diabetol Metab Syndr. 11(94)2019.PubMed/NCBI View Article : Google Scholar
36	Chen D, Jia D, Wu X, Shi K, Ren C, Dou Y, Guo M, Wang J, Ma M, Wu Z, et al: A novel metformin derivative showed improvement of lipid metabolism in obese rats with type 2 diabetes. Clin Exp Pharmacol Physiol. 47:1382–1392. 2020.PubMed/NCBI View Article : Google Scholar